| CPG 1 | CPG 2 | CPG 3 | CPG 4 | CPG 5 | CPG 6 | CPG 7 | CPG 8 | CPG 9 | CPG 10 | CPG 11 | CPG 12 | Total | Percentage (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Domain 1: scope and purpose | ||||||||||||||
 1. Overall objectives specific | 21 | 20 | 21 | 17 | 18 | 18 | 19 | 17 | 15 | 16 | 13 | 14 | 209 | 83 |
 2. Health questions specific | 18 | 20 | 21 | 19 | 21 | 9 | 18 | 16 | 14 | 15 | 13 | 9 | 193 | 77 |
 3. Population is specific | 18 | 21 | 20 | 16 | 20 | 8 | 20 | 17 | 16 | 20 | 17 | 12 | 205 | 81 |
Domain 2: stakeholder involvement | ||||||||||||||
 4. Guideline development group | 19 | 18 | 20 | 15 | 21 | 15 | 18 | 19 | 20 | 7 | 6 | 10 | 188 | 75 |
 5. Views and preferences of target population | 5 | 21 | 18 | 11 | 21 | 6 | 7 | 14 | 2 | 4 | 3 | 3 | 115 | 46 |
 6. Target users clearly defined | 20 | 16 | 20 | 21 | 21 | 16 | 18 | 19 | 18 | 17 | 12 | 4 | 202 | 80 |
Domain 3: rigor of development | ||||||||||||||
 7. Systematic methods | 15 | 17 | 21 | 21 | 21 | 19 | 10 | 13 | 12 | 6 | 16 | 4 | 175 | 69 |
 8. Criteria for evidence selection | 14 | 19 | 21 | 21 | 21 | 17 | 5 | 15 | 19 | 7 | 16 | 4 | 179 | 71 |
 9. Strengths and limitations of evidence | 13 | 19 | 20 | 18 | 18 | 6 | 5 | 20 | 19 | 10 | 9 | 4 | 161 | 64 |
 10. Methods for formulating recommendations | 19 | 17 | 21 | 18 | 19 | 8 | 10 | 21 | 17 | 5 | 8 | 11 | 174 | 69 |
 11. Health benefits, side-effects, risks were considered in formulating recommendations | 20 | 19 | 19 | 17 | 19 | 19 | 21 | 21 | 9 | 18 | 12 | 20 | 214 | 85 |
 12. Explicit link between recommendations and evidence | 19 | 17 | 21 | 20 | 21 | 12 | 10 | 19 | 17 | 11 | 12 | 12 | 191 | 76 |
 13. Externally reviewed prior to publication | 15 | 18 | 21 | 16 | 21 | 6 | 16 | 18 | 15 | 7 | 10 | 9 | 172 | 68 |
 14. A procedure for updating guideline | 13 | 20 | 15 | 20 | 19 | 5 | 4 | 18 | 3 | 3 | 14 | 3 | 137 | 54 |
Domain 4: clarity of presentation | ||||||||||||||
 15. Recommendations specific; unambiguous | 20 | 19 | 21 | 20 | 20 | 18 | 17 | 20 | 17 | 15 | 13 | 18 | 218 | 87 |
 16. Different options for management | 18 | 19 | 14 | 21 | 21 | 20 | 13 | 18 | 18 | 15 | 15 | 16 | 208 | 83 |
 17. Key recommendations easily identifiable | 20 | 19 | 21 | 20 | 21 | 18 | 16 | 20 | 19 | 14 | 12 | 14 | 214 | 85 |
Domain 5: applicability | ||||||||||||||
 18. Barriers and facilitators to application | 15 | 16 | 19 | 20 | 17 | 11 | 6 | 8 | 11 | 4 | 4 | 5 | 136 | 54 |
 19. Advice/Tools to put recommendations to practice | 14 | 20 | 21 | 20 | 18 | 8 | 13 | 10 | 9 | 7 | 8 | 6 | 154 | 61 |
 20. Potential resource limitations have been considered | 9 | 13 | 12 | 18 | 15 | 11 | 7 | 12 | 4 | 3 | 3 | 3 | 110 | 44 |
 21. Monitoring and audit criteria | 15 | 20 | 14 | 20 | 19 | 20 | 9 | 13 | 3 | 8 | 8 | 3 | 152 | 60 |
Domain 6: editorial independence | ||||||||||||||
 22. Views of funding body vs guideline content | 20 | 21 | 21 | 15 | 10 | 20 | 14 | 21 | 12 | 21 | 3 | 17 | 195 | 77 |
 23. Competing interests of guideline development group members have been recorded and addressed | 21 | 21 | 21 | 15 | 20 | 21 | 8 | 21 | 3 | 21 | 3 | 20 | 195 | 77 |